ABSTRACT
OBJECTIVE:
To evaluate the clinical effect of high-
dose intravenous immunoglobulin (HDIVIG)
single dose and
pulse therapy combined with small-
dose prednisone acetate in the
treatment of
patients with
Kawasaki disease (KD).
METHODS:
Eighty
patients with KD from Baoding
Children's
Hospital,
China, were randomly divided into two groups the experimental group and the
control group, each with 40 cases.
Patients in the experimental group were treated with HDIVIG
single dose,
pulse therapy combined with low-
dose prednisone acetate, while
patients in the
control group were treated with conventional-
dose immunoglobulin.
Patients in both groups were treated with
aspirin orally, and given symptomatic
treatment including anti-inflammatory,
nutritional support, correction of
water and
electrolyte disturbance and
acid-base balance. Peripheral venous
blood samples were drawn from all
patients at the
time of admission, Day-1, Day-7 and Day-14
after treatment, and in the basic
state of getting up in the morning, and then the levels of
tumor necrosis factor (TNF-a),
C-reactive protein (CRP),
interleukin-6 (
IL-6) and other inflammatory factors were detected by
enzyme-linked immunosorbent assay (
ELISA). The
time of
body temperature falling to normal,
lymph node swelling recovery,
hands and
feet swelling, mucosal
hyperemia regression
after treatment in the two groups was recorded, and the
treatment effect of the two groups was comprehensively evaluated.
RESULTS:
After treatment, the levels of inflammatory factors such as TNF-a, CRP,
IL-6 in the experimental group were significantly lower than those in the
control group, with a statistically significant difference (P<0.05). In addition, the
time of
body temperature falling to normal,
lymph node swelling recovery,
hands and
feet swelling, and mucosal
hyperemia regression in the experimental group was significantly shorter than that in the
control group (p=0.00). The effective rate of the experimental group was 95% and that of the
control group was 80%, with a statistically significant difference (p=0.04).
CONCLUSION:
HDIVIG
single dose,
pulse therapy combined with small-
dose prednisone acetate has a favourable
therapeutic effect in the
treatment of
patients with KD, by which the inflammatory factors can be significantly improved, clinical symptoms and weight can be quickly ameliorated, and
therapeutic effect can be enhanced.
